PT  - JOURNAL ARTICLE
AU  - Adamson, Walt E.
AU  - Noyes, Harry
AU  - Johnson, Paul
AU  - Cooper, Anneli
AU  - Monckton, Darren G.
AU  - Ogunsola, John
AU  - Sullivan, Michael
AU  - Mark, Patrick
AU  - Parekh, Rulan S.
AU  - MacLeod, Annette
AU  - ,
TI  - Phenome-wide analysis of <em>APOL1</em> risk variants reveals associations between one combination of haplotypes and multiple disease phenotypes in addition to chronic kidney disease
AID  - 10.1101/2023.02.19.23285950
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.19.23285950
4099  - http://medrxiv.org/content/early/2023/02/23/2023.02.19.23285950.short
4100  - http://medrxiv.org/content/early/2023/02/23/2023.02.19.23285950.full
AB  - Background Infectious diseases are a major driving force of natural selection. One human gene associated with strong evolutionary selection is APOL1. Two APOL1 variants, G1 and G2, emerged in sub-Saharan Africa in the last 10,000 years, possibly due to protection from the fatal African sleeping sickness, analogous to Plasmodium-driven selection of the sickle-cell trait. As homozygosity for the HbS allele causes sickle cell anaemia, homozygosity for the APOL1 G1 and G2 variants has also been associated with chronic kidney disease (CKD) and other kidney-related conditions. What is not known is the extend of non-kidney-related disorders and if there are clusters of diseases associated with individual APOL1 genotypes.Methods Using principal component analysis, we identified a cohort of 10,179 UK Biobank participants with recent African ancestry. We conducted a phenome-wide association test between all combinations of APOL1 G1 and G2 genotypes and conditions identified with International Classification of Disease phenotypes using Firth’s bias-reduced logistic regression and a false discovery rate to correct for multiple testing. We further examined associations with chronic kidney disease indicators: estimated glomerular filtration rate (eGFR) and urinary albumin:creatinine (uACR).Results The phenome-wide screen revealed 74 (mostly deleterious) potential associations with hospitalisation for a range of conditions. G1/G2 compound heterozygotes were specifically associated with hospitalisation in 64 (86.5%) of these conditions, with an over-representation of infectious diseases (including COVID-19) and endocrine, nutritional, and metabolic diseases. The analysis also revealed complexities in the relationship between APOL1 and CKD that are not evident when the risk variants are grouped together: high uACR was associated specifically with G1 homozygosity; low eGFR with G2 homozygosity and G1/G2 compound heterozygosity; progression to end stage kidney disease was associated with G1/G2 compound heterozygosity.Conclusions Among 9,594 participants, stratifying individual APOL1 risk variant genotypes had a differential effect on associations with both kidney and non-kidney phenotypes. The compound heterozygous G1/G2 genotype was distinguished as uniquely deleterious in its association with a range of ICD-10 phenotypes. The epistatic nature of the G1/G2 interaction means that such associations may go undetected in a standard genome-wide association study. These observations have the potential to significantly impact the way that health risks are understood, particularly in populations where APOL1 G1 and G2 are common such as in sub-Saharan Africa and its diaspora.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Wellcome Trust (209511/Z/17/Z) and H3Africa (H3A/18/004).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Access to the UK Biobank data was granted for this work under UK Biobank application number 66821.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis research has been conducted using the UK Biobank Resource under application number 66821. All bona fide researchers can apply to use the UK Biobank resource for health related research that is in the public interest. https://www.ukbiobank.ac.uk